Personal Finance

Is Acadia Pharmaceuticals Stock Now a Strong Buy?

A man in business attire drawing an upward-sloping sales curve

What happened

Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing novel treatments for disorders of the central nervous system, saw its shares fall by a noteworthy 17.7% last month, according to S&P Global Market Intelligence .

What's going on? The company's fourth-quarter sales of its drug for Parkinson's disease psychosis, Nuplazid, came in slightly below consensus for the three-month period, triggering a mass exodus among shareholders.

A man in business attire drawing an upward-sloping sales curve

Image source: Getty Images.

So what

Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. The underlying reason is that early shareholders seemed to believe that Nuplazid would go supernova, from a sales standpoint, right out of the gate.

While the drug is performing admirably, with a projected run rate of between $255 million and $270 million for 2018, these sales forecasts are well below the $3 billion or more that some investors and analysts were touting prior to FDA approval.

Now what

The silver lining is that Nuplazid has been far from the total flop some analysts were predicting early on. In fact, the drug's sales are expected to reach a healthy $443 million in 2019.

The downside, however, is that even this stately annual haul still equates to Acadia's shares trading at a forward price-to-sales ratio in excess of 7. That's among the highest in the biopharmaceutical space -- suggesting that Acadia's stock remains on the expensive side.

When is it time to buy? My view is that Acadia won't be in bargain territory until it either loses another 20% (at a minimum), or the company addresses its long-term financing needs by striking a front-loaded licensing deal for Nuplazid's other potential indications. As things stand now, Acadia will probably have to resort to a massive secondary offering in early 2019 to pay for Nuplazid's other clinical trials.

10 stocks we like better than Acadia Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of March 5, 2018

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ACAD

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More